Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zealand Pharma A/S (ZEAL.CO)
Copenhagen, DK
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.58% | +12.35% | +20.43% | -14.08% | -26.83% | -24.67% | -18.62% | +41.12% | +86.44% | +194.98% | +303.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 8 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Biotechnology: +1.6%+14,598.9% ★ Q1'26: +320.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+655.5% ★ Q1'26: -17.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+72.3% Q1'26: -2,005.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+77.7% ★ Q1'26: -1,585.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+3,175.3% ★ Q1'26: -519.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.7% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.07× ★ Q1'26: -0.20× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 14 Rev. Ana. 11 EPS Ana. |
Dec 2027 15 Rev. Ana. 13 EPS Ana. |
Dec 2028 11 Rev. Ana. 9 EPS Ana. |
Dec 2029 5 Rev. Ana. 3 EPS Ana. |
Dec 2030 5 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
187.68M
est: 192.80M (-2.7%)
|
234.78M
est: 239.42M (-1.9%)
|
139.78M
est: 146.92M (-4.9%)
|
37.98M
est: 32.26M (+17.7%)
|
41.33M
est: 142.19M (-70.9%)
|
353.31M
est: 376.09M (-6.1%)
|
292.57M
est: 291.75M (+0.3%)
|
103.99M
est: 149.85M (-30.6%)
|
342.79M
est: 367.97M (-6.8%)
|
62.69M
est: 74.15M (-15.5%)
|
9.21B
est: 9.23B (-0.1%)
|
4.46B
3.64B – 5.03B
-51.7% YoY
|
4.26B
1.13B – 5.96B
-4.5% YoY
|
1.47B
1.43B – 1.52B
-65.4% YoY
|
3.30B
1.81B – 4.16B
+124.4% YoY
|
4.74B
2.60B – 5.98B
+43.6% YoY
|
| EBITDA |
-75.11M
est: -192.80M (+61.0%)
|
-113.22M
est: -239.42M (+52.7%)
|
-250.39M
est: -146.92M (-70.4%)
|
-442.00M
est: -32.26M (-1,270.2%)
|
-559.74M
est: -142.19M (-293.7%)
|
-583.54M
est: -376.09M (-55.2%)
|
-729.68M
est: -291.75M (-150.1%)
|
-884.88M
est: -149.85M (-490.5%)
|
-651.58M
est: -237.01M (-174.9%)
|
-1.02B
est: -47.76M (-2,028.8%)
|
7.18B
est: -5.94B (+220.9%)
|
-2.87B
-3.24B – -2.34B
+51.7% YoY
|
-2.74B
-3.84B – -729.77M
+4.5% YoY
|
-947.73M
-976.54M – -918.92M
+65.4% YoY
|
-2.13B
-2.68B – -1.17B
-124.4% YoY
|
-3.05B
-3.85B – -1.67B
-43.6% YoY
|
| EBIT |
-87.46M
est: -192.80M (+54.6%)
|
-118.63M
est: -239.42M (+50.5%)
|
-255.15M
est: -146.92M (-73.7%)
|
640.13M
est: -32.26M (+2,084.4%)
|
-573.29M
est: -142.19M (-303.2%)
|
-670.63M
est: -376.09M (-78.3%)
|
-754.80M
est: -291.75M (-158.7%)
|
-915.59M
est: -149.85M (-511.0%)
|
-679.88M
est: -237.23M (-186.6%)
|
-1.04B
est: -47.80M (-2,080.9%)
|
7.16B
est: -5.95B (+220.3%)
|
-2.87B
-3.24B – -2.35B
+51.7% YoY
|
-2.74B
-3.84B – -730.45M
+4.5% YoY
|
-948.61M
-977.44M – -919.77M
+65.4% YoY
|
-2.13B
-2.68B – -1.17B
-124.4% YoY
|
-3.06B
-3.85B – -1.68B
-43.6% YoY
|
| Net Income |
-113.96M
est: -199.23M (+42.8%)
|
-153.91M
est: -387.58M (+60.3%)
|
-272.27M
est: -647.62M (+58.0%)
|
581.28M
est: 1.24B (-53.2%)
|
-571.54M
est: -825.05M (+30.7%)
|
-846.73M
est: -1.20B (+29.4%)
|
-1.02B
est: -1.81B (+43.9%)
|
-965.61M
est: -986.08M (+2.1%)
|
-703.74M
est: -712.00M (+1.2%)
|
-1.08B
est: -946.51M (-14.0%)
|
6.46B
est: 6.40B (+0.9%)
|
1.51B
1.12B – 1.81B
-76.4% YoY
|
411.07M
-2.30B – 3.10B
-72.8% YoY
|
-2.69B
-4.91B – 2.80B
-753.6% YoY
|
-769.26M
-1.03B – -317.35M
+71.4% YoY
|
326.09M
134.52M – 436.61M
+142.4% YoY
|
| SGA |
44.61M
est: 401.87M (-88.9%)
|
52.50M
est: 499.04M (-89.5%)
|
47.47M
est: 306.25M (-84.5%)
|
78.00M
est: 67.24M (+16.0%)
|
67.88M
est: 296.37M (-77.1%)
|
488.03M
est: 783.92M (-37.7%)
|
636.26M
est: 608.13M (+4.6%)
|
306.54M
est: 312.35M (-1.9%)
|
89.85M
est: 669.26M (-86.6%)
|
229.20M
est: 134.86M (+70.0%)
|
489.49M
est: 16.78B (-97.1%)
|
8.11B
6.62B – 9.15B
-51.7% YoY
|
7.74B
2.06B – 10.84B
-4.5% YoY
|
2.68B
2.59B – 2.76B
-65.4% YoY
|
6.01B
3.29B – 7.57B
+124.4% YoY
|
8.62B
4.73B – 10.87B
+43.6% YoY
|
| EPS |
-4.94
est: -3.00 (-64.7%)
|
-6.33
est: -5.83 (-8.5%)
|
-9.77
est: -9.75 (-0.2%)
|
18.94
est: 18.69 (+1.4%)
|
-16.91
est: -12.42 (-36.2%)
|
-22.07
est: -18.06 (-22.2%)
|
-23.75
est: -27.32 (+13.1%)
|
-20.90
est: -23.38 (+10.6%)
|
-12.44
est: -11.82 (-5.3%)
|
-16.24
est: -15.11 (-7.5%)
|
91.56
est: 90.66 (+1.0%)
|
19.73
15.65 – 25.29
-78.2% YoY
|
8.76
-32.21 – 43.38
-55.6% YoY
|
-39.17
-68.57 – 39.08
-547.4% YoY
|
-10.75
-14.40 – -4.44
+72.5% YoY
|
4.56
1.88 – 6.10
+142.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adam Sinding Steensberg | President & Chief Executive Officer | 23M | male |
| Henriette Wennicke | EVP & CFO | 10M | female |
| David Kendall | Executive Vice President, Chief Medical Officer & Head of R&D | — | — |
| Eric Cox | Executive Vice President & Chief Commercial Officer | — | male |
| Eric Rojas | VP & Head of Investor Relations | — | male |
| Ivan Mourits Moller | Executive Vice President & Chief Operating Officer | — | male |
| Jens Damsgaard Mikkelsen | Head of Molecular Pharmacology | — | — |
| Ravinder Chahil | EVP & General Counsel | — | male |
| Adam Lange | Vice President of Investor Relations | — | — |
| Utpal Singh | Executive VP & Chief Scientific Officer | — | male |
| Christina Sonnenborg Bredal | Executive Vice President & Chief People Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ZEAL.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
